Federal Funding Cut Threatens Pediatric Brain Tumor Research

Federal funding crucial for pediatric brain tumor research is ending by March 2026, impacting critical clinical trials and research networks. The Pediatric Brain Tumor Consortium (PBTC), an alliance of 15 hospitals including Children's Hospital Colorado, has been instrumental in developing new treatments for childhood cancers. Its annual budget of approximately $4 million is now in jeopardy, causing distress among medical professionals and families who have relied on its work. Dr. Lia Gore, head of pediatric oncology at Children's Hospital Colorado, describes the funding cut as a "direct insult" to those dedicated to this research. The NIH states that this transition into the Pediatric Early Phase Clinical Trials Network (PEP CTN) is not a cost-cutting measure and that pediatric brain tumor research remains a priority. However, parents like Jeremy Nemeth, whose daughter Marin battled a rare brain tumor, express deep anger and devastation, viewing the PBTC as a "glimmer of hope" for experimental treatments. They fear that this decision prioritizes financial waste over the potential for children to live full lives.